Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Budesonide/Formoterol Teva Pharma B.V., budesonide,formoter...

 

 
 
Human medicines European public assessment report (EPAR): Budesonide/Formoterol Teva Pharma B.V., budesonide,formoterol fumarate dihydrate, Asthma,Pulmonary Disease, Chronic Obstructive, Date of authorisation: 03/04/2020, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Budesonide/Formoterol Teva Pharma B.V., budesonide,formoterol fumarate dihydrate, Asthma,Pulmonary Disease, Chronic Obstructive, Date of authorisation: 03/04/2020, Revision: 1, Status: Authorised



 
 
Update werkgroep Corona
13 juli 2021 Gezien de huidige ontwikkelingen rond de coronapandemie is de werkgroep Corona weer actief.Lees verder



 
 
BioFire Diagnostics, LLC, FSN-FSCA 5183, PN plus Panel
The purpose of this letter is to inform you that BioFire Diagnostics, LLC has identified a potential for elevated rates of false negative Adenovirus results when using the BioFire® PN or PN plus Panels.


Actueel zorgnieuws in jouw mailbox ontvangen?
Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.